6-Bromo-5-nitroindolin-2-one | 557093-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-Bromo-5-nitroindolin-2-one
• 英文别名: 6-bromo-5-nitro-1,3-dihydroindol-2-one
• CAS: 557093-47-7
• 化学式: C8H5BrN2O3
• 分子量: 257.04
• InChiKey: ODXRNFSDBWGNEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Bromo-5-nitroindolin-2-one 在 盐酸 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 26.0h， 生成
  参考文献：
  名称：

  10.1016/j.bmc.2024.117752

  摘要：

  DOI：

  10.1016/j.bmc.2024.117752
• 作为产物：
  描述：

  6-溴-2-羟吲哚 在 硫酸 、 potassium nitrate 作用下， 生成 6-Bromo-5-nitroindolin-2-one
  参考文献：
  名称：

  10.1016/j.bmc.2024.117752

  摘要：

  DOI：

  10.1016/j.bmc.2024.117752

文献信息

• Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
  申请人：Berg Stefan

  公开号：US20050070559A1

  公开（公告）日：2005-03-31

  The present invention relates to a new use of oxindole derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , m and n arm as defined as in claim 1, as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3.

  本发明涉及一种公式I的氧化吲哚衍生物的新用途，作为其自由碱基或药学上可接受的盐，其中R1、R2、R3、m和n的定义如权利要求书1所述。同时涉及新化合物、其制备方法以及用于制备新化合物的新中间体，含有所述治疗活性化合物的药物组合物以及所述活性化合物在治疗中的应用，特别是在预防和/或治疗与糖原合成酶激酶-3相关的痴呆症、阿尔茨海默病和条件方面的应用。
• Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3
  申请人：Berg Stefan

  公开号：US20090312322A1

  公开（公告）日：2009-12-17

  The present invention relates to a new use of oxindole derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof, [Chemical formula should be inserted here. Please see paper copy.] wherein R 1 , R 2 , R 3 , m and n are as defined as in claim 1 , as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3.

  本发明涉及一种新的使用氧吲哚衍生物的公式I，作为其自由碱基或药学上可接受的盐，[化学式应在此处插入。请参阅纸质副本。]其中R1、R2、R3、m和n的定义如权利要求1所述，以及新的化合物、其制备过程和用于制备中的新中间体，含有这些治疗活性化合物的药物组合物以及在疗法中使用这些活性化合物，特别是在预防和/或治疗与糖原合成酶激酶-3相关的痴呆症、阿尔茨海默病和条件方面的应用。
• USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3
  申请人：AstraZeneca AB

  公开号：EP1458394A1

  公开（公告）日：2004-09-22
• [EN] USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3<br/>[FR] UTILISATION DE DERIVES D'OXINDOLE DANS LE TRAITEMENT DES MALADIES ASSOCIEES A LA DEMENCE, LA MALADIE D'ALZHEIMER ET LES ETATS PATHOLOGIQUES ASSOCIES A LA GLYCOGENE SYNTHASE KINASE-3
  申请人：ASTRAZENECA AB

  公开号：WO2003055492A1

  公开（公告）日：2003-07-10

  The present invention relates to a new use of oxindole derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof, [Chemical formula should be inserted here. Please see paper copy.]wherein R1, R2, R3, m and n are as defined as in claim 1, as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3.